Alligator Bioscience Logo
SE0024173637
A41BED

Alligator Bioscience

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Alligator Bioscience stops Mitazalimab development, stock plunges 74%

    Alligator Bioscience’s board has halted further independent development of the CD40 antibody Mitazalimab due to the rapidly changing treatment landscape in pancreatic cancer and intends to out-license or sell the drug. Resources will be redirected to HLX22 (anti-HER2), which is being developed externally by Shanghai Henlius Biotech; Alligator will receive revenue participation for this without development expense. The company also announced a rights issue of around SEK 125.6 million and a bridge financing; cash of SEK 33 million will only last until mid-Q3 2026. The combination of the project halt, a heavily dilutive capital measure and strained liquidity triggered the sharp share price decline. » Altro su de.investing.com


  • Alligator Bioscience cuts costs sharply and plans phase‑III start for mitazalimab

    Alligator Bioscience reports significant cost reductions in Q1 2026 (annualized operating costs cut from 300 to 100 million SEK; Q1 costs 17 million SEK) and reports cash of 33 million SEK. Lead candidate mitazalimab showed a 30‑month survival rate of 20% in Phase II, and the company is preparing to start a Phase‑III trial in Q4 2026; a regulatory submission is expected in Q2 2026. Because cash is only expected to last until mid‑Q3 2026, Alligator is actively exploring financing options. The stock rose 4.69% following the results. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Alligator Bioscience ha registrato ricavi pari a 20,9K € e un utile netto di -1,47 Mln €
(EUR) settembre 2026
YoY
Ricavi 20,9K 50,63%
Utile lordo -1,31 Mln -
Utile netto -1,47 Mln 32,53%
EBITDA -1,72 Mln 155,43%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
41,96K €
Numero di azioni
53,09 Mln
Massimo/minimo a 52 settimane
0,11 € - 0,000781 €
Dividendi No
Beta
1,17
Rapporto P/E
-0,01
Rapporto PEG
0,00
Rapporto P/B
0,24
Rapporto P/S
1,65

Profilo aziendale

Nome
Alligator Bioscience
CEO
Søren Bregenholt
Dipendenti 11
🍪

Parqet  usa i cookie. Scopri di più